Cardiovascular drug development: Is it dead or just hibernating?

Christopher B. Fordyce; Matthew T. Roe; Tariq Ahmad; Peter Libby; Jeffrey S. Borer; William R. Hiatt; Michael R. Bristow; Milton Packer; Scott M. Wasserman; Ned Braunstein; Bertram Pitt; David L. Demets; Katharine Cooper-Arnold; Paul W. Armstrong; Scott D. Berkowitz; Rob Scott; Jayne Prats; Zorina S. Galis; Norman Stockbridge; Eric D. Peterson; Robert M. Califf

doi:10.1016/j.jacc.2015.03.016

Cardiovascular drug development: Is it dead or just hibernating?

Christopher B. Fordyce, Matthew T. Roe, Tariq Ahmad, Peter Libby, Jeffrey S. Borer, William R. Hiatt, Michael R. Bristow, Milton Packer, Scott M. Wasserman, Ned Braunstein, Bertram Pitt, David L. Demets, Katharine Cooper-Arnold, Paul W. Armstrong, Scott D. Berkowitz, Rob Scott, Jayne Prats, Zorina S. Galis, Norman Stockbridge, Eric D. PetersonRobert M. Califf

Research output: Contribution to journal › Review article › peer-review

143 Scopus citations

Abstract

Despite the global burden of cardiovascular disease, investment in cardiovascular drug development has stagnated over the past 2 decades, with relative underinvestment compared with other therapeutic areas. The reasons for this trend are multifactorial, but of primary concern is the high cost of conducting cardiovascular outcome trials in the current regulatory environment that demands a direct assessment of risks and benefits, using clinically-evident cardiovascular endpoints. To work toward consensus on improving the environment for cardiovascular drug development, stakeholders from academia, industry, regulatory bodies, and government agencies convened for a think tank meeting in July 2014 in Washington, DC. This paper summarizes the proceedings of the meeting and aims to delineate the current adverse trends in cardiovascular drug development, understand the key issues that underlie these trends within the context of a recognized need for a rigorous regulatory review process, and provide potential solutions to the problems identified.

Original language	English (US)
Pages (from-to)	1567-1582
Number of pages	16
Journal	Journal of the American College of Cardiology
Volume	65
Issue number	15
DOIs	https://doi.org/10.1016/j.jacc.2015.03.016
State	Published - Apr 21 2015

Keywords

biomarkers
cardiovascular agents
clinical trials
drug costs
pharmacological
policy

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacc.2015.03.016

Cite this

Fordyce, C. B., Roe, M. T., Ahmad, T., Libby, P., Borer, J. S., Hiatt, W. R., Bristow, M. R., Packer, M., Wasserman, S. M., Braunstein, N., Pitt, B., Demets, D. L., Cooper-Arnold, K., Armstrong, P. W., Berkowitz, S. D., Scott, R., Prats, J., Galis, Z. S., Stockbridge, N., ... Califf, R. M. (2015). Cardiovascular drug development: Is it dead or just hibernating? Journal of the American College of Cardiology, 65(15), 1567-1582. https://doi.org/10.1016/j.jacc.2015.03.016

Fordyce, CB, Roe, MT, Ahmad, T, Libby, P, Borer, JS, Hiatt, WR, Bristow, MR, Packer, M, Wasserman, SM, Braunstein, N, Pitt, B, Demets, DL, Cooper-Arnold, K, Armstrong, PW, Berkowitz, SD, Scott, R, Prats, J, Galis, ZS, Stockbridge, N, Peterson, ED & Califf, RM 2015, 'Cardiovascular drug development: Is it dead or just hibernating?', Journal of the American College of Cardiology, vol. 65, no. 15, pp. 1567-1582. https://doi.org/10.1016/j.jacc.2015.03.016

@article{d9e9c9eedec844d49699879b8de02aa1,

title = "Cardiovascular drug development: Is it dead or just hibernating?",

abstract = "Despite the global burden of cardiovascular disease, investment in cardiovascular drug development has stagnated over the past 2 decades, with relative underinvestment compared with other therapeutic areas. The reasons for this trend are multifactorial, but of primary concern is the high cost of conducting cardiovascular outcome trials in the current regulatory environment that demands a direct assessment of risks and benefits, using clinically-evident cardiovascular endpoints. To work toward consensus on improving the environment for cardiovascular drug development, stakeholders from academia, industry, regulatory bodies, and government agencies convened for a think tank meeting in July 2014 in Washington, DC. This paper summarizes the proceedings of the meeting and aims to delineate the current adverse trends in cardiovascular drug development, understand the key issues that underlie these trends within the context of a recognized need for a rigorous regulatory review process, and provide potential solutions to the problems identified.",

keywords = "biomarkers, cardiovascular agents, clinical trials, drug costs, pharmacological, policy",

author = "Fordyce, {Christopher B.} and Roe, {Matthew T.} and Tariq Ahmad and Peter Libby and Borer, {Jeffrey S.} and Hiatt, {William R.} and Bristow, {Michael R.} and Milton Packer and Wasserman, {Scott M.} and Ned Braunstein and Bertram Pitt and Demets, {David L.} and Katharine Cooper-Arnold and Armstrong, {Paul W.} and Berkowitz, {Scott D.} and Rob Scott and Jayne Prats and Galis, {Zorina S.} and Norman Stockbridge and Peterson, {Eric D.} and Califf, {Robert M.}",

note = "Publisher Copyright: {\textcopyright} 2015 American College of Cardiology Foundation.",

year = "2015",

month = apr,

day = "21",

doi = "10.1016/j.jacc.2015.03.016",

language = "English (US)",

volume = "65",

pages = "1567--1582",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier USA",

number = "15",

}

TY - JOUR

T1 - Cardiovascular drug development

T2 - Is it dead or just hibernating?

AU - Fordyce, Christopher B.

AU - Roe, Matthew T.

AU - Ahmad, Tariq

AU - Libby, Peter

AU - Borer, Jeffrey S.

AU - Hiatt, William R.

AU - Bristow, Michael R.

AU - Packer, Milton

AU - Wasserman, Scott M.

AU - Braunstein, Ned

AU - Pitt, Bertram

AU - Demets, David L.

AU - Cooper-Arnold, Katharine

AU - Armstrong, Paul W.

AU - Berkowitz, Scott D.

AU - Scott, Rob

AU - Prats, Jayne

AU - Galis, Zorina S.

AU - Stockbridge, Norman

AU - Peterson, Eric D.

AU - Califf, Robert M.

PY - 2015/4/21

Y1 - 2015/4/21

N2 - Despite the global burden of cardiovascular disease, investment in cardiovascular drug development has stagnated over the past 2 decades, with relative underinvestment compared with other therapeutic areas. The reasons for this trend are multifactorial, but of primary concern is the high cost of conducting cardiovascular outcome trials in the current regulatory environment that demands a direct assessment of risks and benefits, using clinically-evident cardiovascular endpoints. To work toward consensus on improving the environment for cardiovascular drug development, stakeholders from academia, industry, regulatory bodies, and government agencies convened for a think tank meeting in July 2014 in Washington, DC. This paper summarizes the proceedings of the meeting and aims to delineate the current adverse trends in cardiovascular drug development, understand the key issues that underlie these trends within the context of a recognized need for a rigorous regulatory review process, and provide potential solutions to the problems identified.

AB - Despite the global burden of cardiovascular disease, investment in cardiovascular drug development has stagnated over the past 2 decades, with relative underinvestment compared with other therapeutic areas. The reasons for this trend are multifactorial, but of primary concern is the high cost of conducting cardiovascular outcome trials in the current regulatory environment that demands a direct assessment of risks and benefits, using clinically-evident cardiovascular endpoints. To work toward consensus on improving the environment for cardiovascular drug development, stakeholders from academia, industry, regulatory bodies, and government agencies convened for a think tank meeting in July 2014 in Washington, DC. This paper summarizes the proceedings of the meeting and aims to delineate the current adverse trends in cardiovascular drug development, understand the key issues that underlie these trends within the context of a recognized need for a rigorous regulatory review process, and provide potential solutions to the problems identified.

KW - biomarkers

KW - cardiovascular agents

KW - clinical trials

KW - drug costs

KW - pharmacological

KW - policy

UR - http://www.scopus.com/inward/record.url?scp=84928036813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928036813&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2015.03.016

DO - 10.1016/j.jacc.2015.03.016

M3 - Review article

C2 - 25881939

AN - SCOPUS:84928036813

SN - 0735-1097

VL - 65

SP - 1567

EP - 1582

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 15

ER -

Cardiovascular drug development: Is it dead or just hibernating?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this